Miles Congreve

List of Publications by Year
in descending order

20 papers	2,170 citations	567281 15 h-index	752698 20 g-index
20 all docs	20 docs citations	20 times ranked	2548 citing authors

#	Article	IF	Citations
1	Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Proteinâ€“Ligand Complexes. ACS Chemical Neuroscience, 2022, 13, 751-765.	3.5	4
2	Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. Journal of Medicinal Chemistry, 2020, 63, 905-927.	6.4	34
3	Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. Journal of Medicinal Chemistry, 2020, 63, 1528-1543.	6.4	46
4	Xâ€Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A_{2A} Adenosine Receptor Antagonists. Angewandte Chemie - International Edition, 2020, 59, 16536-16543.	13.8	23
5	Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation. Journal of Chemical Information and Modeling, 2020, 60, 5563-5579.	5.4	45
6	Structure-Based Drug Discovery of N-((R)-3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(((S)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propa (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine. Journal of Medicinal Chemistry, 2020, 63, 7906-7920.	6.4	13
7	Xâ€Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A_{2A} Adenosine Receptor Antagonists. Angewandte Chemie, 2020, 132, 16679-16686.	2.0	1
8	Impact of GPCR Structures on Drug Discovery. Cell, 2020, 181, 81-91.	28.9	229
9	Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu₅) X-ray Structures. Journal of Medicinal Chemistry, 2019, 62, 207-222.	6.4	67
10	Abstract 3751: Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models. Cancer Research, 2018, 78, 3751-3751.	0.9	8
11	Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs. Trends in Pharmacological Sciences, 2017, 38, 837-847.	8.7	106
12	Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature, 2017, 546, 254-258.	27.8	155
13	Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. MedChemComm, 2015, 6, 947-955.	3.4	15
14	Structure-based drug design of chromone antagonists of the adenosine A_{2A} receptor. MedChemComm, 2014, 5, 571-575.	3.4	24
15	Discovery of 1,2,4-Triazine Derivatives as Adenosine A_{2A} Antagonists using Structure Based Drug Design. Journal of Medicinal Chemistry, 2012, 55, 1898-1903.	6.4	296
16	Identification of Novel Adenosine A_{2A} Receptor Antagonists by Virtual Screening. Journal of Medicinal Chemistry, 2012, 55, 1904-1909.	6.4	131
17	New insights from structural biology into the druggability of G protein-coupled receptors. Trends in Pharmacological Sciences, 2012, 33, 249-260.	8.7	158
18	Progress in Structure Based Drug Design for G Protein-Coupled Receptors. Journal of Medicinal Chemistry, 2011, 54, 4283-4311.	6.4	203

#	Article	IF	Citations
19	Biophysical Mapping of the Adenosine A_{2A} Receptor. Journal of Medicinal Chemistry, 2011, 54, 4312-4323.	6.4	107
20	Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. Structure, 2011, 19, 1283-1293.	3.3	505